COLL
Collegium·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Strong Buy"
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About COLL
Collegium Pharmaceutical, Inc.
A leading specialty pharmaceutical company that develops generic and branded drugs primarily for the treatmet of chronic pain and other diseases
100 Technology Center Drive, Stoughton, MA 02072
--
Collegium Pharmaceutical, Inc., was incorporated in Delaware in April 2002 and subsequently re-incorporated in Virginia in July 2014. The company's mission is to build a leading and diversified specialty pharmaceutical company dedicated to improving the lives of critically ill patients. The company has leveraged R&D efforts and acquisition and licensing relationships with third parties to develop a meaningful range of differentiated products for the treatment of moderate to severe pain.
Earnings Call
Q2/2025
Estimate EPS1.85
Actual EPS1.68
Estimate Revenue180.88M
Actual Revenue188.00M
Collegium Pharmaceutical's Q2 2025: Key Contradictions on Jornay PM Sales Estimates and Pain Portfolio Competition
Aug 10,2025 11:25
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
COLL has released its 2025 Q3 earnings. EPS was reported at 2.25, versus the expected 1.86, beating expectations. The chart below visualizes how COLL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
COLL has released its 2025 Q3 earnings report, with revenue of 209.36M, reflecting a YoY change of 31.42%, and net profit of 31.51M, showing a YoY change of 237.51%. The Sankey diagram below clearly presents COLL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
